Jones Soda Co. Third Quarter 2026 Earnings Call - JONES SODA CO

Financial Performance:

• Q3 2026 revenue reached a record $13.7 million, a 204% increase year-over-year ($4.5M in Q3 2025), driven by volume sales of Fallout-branded products and the recognition of $2 million in shipments shifted from Q2.
• Gross margin expanded to 34.4% in Q3 (up from 28.9% YoY and 27.5% sequentially), marking a 550 bps improvement year-over-year, despite the wind-down of the higher-margin hemp-derived (HT9) beverage business.
• The company reported profitability in Q3 with net income from continuing operations of $471,000 ($0.00 per share) and Adjusted EBITDA of $869,000, representing a $1.77 million YoY improvement.
• For the nine months ended September 30, 2026, revenue totaled $36.3 million (up 167% YoY), with Adjusted EBITDA positive at $1.12 million compared to a $2.65 million loss in the prior period.
• Operating expenses increased to $4.3 million in Q3 due to higher selling and marketing costs (broker fees, royalties) associated with Fallout sales, though OPEX as a percentage of revenue dropped significantly to 32% from 60% YoY.
• Balance sheet strength improved with cash reserves reaching $4.4 million as of September 30, 2026, while working capital increased; Accounts Receivable rose to $5.6 million (99% current in the US) and Inventory increased to $6.5 million to support channel growth.
• Revolving credit facility usage stands at $3.5 million; the company completed two private placements in 2026 to strengthen cash resources.

Guidance and Future Outlook:

• The company reaffirmed full-year 2026 guidance: revenue expected to exceed $45 million (representing >80% growth over 2025) and positive Adjusted EBITDA for the full year.
• No specific revenue or earnings guidance has been issued for fiscal 2027 at this time, with expectations for updated board-approved guidance to be announced early in 2027.
• Management targets an S-1 update and filing with the SEC before year-end, aiming for a potential uplisting to NYSE or NASDAQ in the first quarter of 2027.
• Long-term strategy is built on three growth pillars: Core Beverage, Consumer Lifestyle (partnerships/licensing), and Functional Health and Nutrition (via Jones Labs).
• Jones Labs product testing is scheduled to begin in Q1 2027, focusing on metabolic health, GLP-1 support, performance nutrition, and gut health categories.
• Direct-to-consumer (D2C) platform relaunch is targeted for January 2027, featuring a redesigned website, subscription offerings, and improved customer retention capabilities.

Business Segments and Product Lines:

• Club Channels: The primary growth driver, led by Fallout branded products; launched in 250+ HEB stores in Texas with eight facings.
• Direct-to-Consumer: Projected to reach ~$5 million in annual revenue for 2026 (up from $100k in 2024), driven by high-demand collectibles like "Fallout Rocket Bottles" ($50 each), which sold out within a week and surpassed 11,000 sales.
• Core Beverage: Introduction of a "Zero Sugar" lineup in Western Canada and US retailers to recapture lapsed consumers; new product development will now parallel full-sugar and zero-sugar options.
• Portfolio Rationalization: Discontinued "Spike Jones" and "Pop Jones" lines due to low velocity and competitive pressure; discontinued select legacy flavors (e.g., Coal, Limelight) based on product mix efficiency.
• Licensing Partnerships: Celebrated 30th anniversary with Crayola collaboration; new partnerships and licensed products are expected to be announced by year-end or early 2027.

Market and Competitive Landscape:

• Jones Soda is outperforming the broader craft soda market, which is generally in decline, achieving significant growth while competitors struggle.
• Management emphasizes agility and creativity compared to larger beverage incumbents, enabling faster time-to-market for niche products and collaborations.
• The company is leveraging the Fallout partnership to secure shelf space and retailer relationships that were previously inaccessible, using these as foot-in-the-door opportunities for broader portfolio distribution.
• Interest from non-beverage brands for strategic partnerships (licensing/brand extensions) is increasing, though no inquiries regarding acquisition from major beverage companies have materialized.

Risks and Challenges:

• Margin Volatility: Quarterly margins remain sensitive to freight rates, product mix, and shipment timing, though efforts are underway to reduce logistics costs via RFP negotiations.
• Concentration Risk: Heavy reliance on the Fallout partnership raises questions about long-term sustainability post-agreement, though management notes two years remaining and multiple rotations planned.
• Working Capital: Significant inventory buildup ($6.5M) and increased receivables require careful management to ensure cash conversion as revenue scales.
• Competition: High competition in the functional health and zero-sugar categories requires careful differentiation to avoid commoditization (as seen with the exit from Pop Jones).
• Execution Risk: Reliance on successful integration of new systems, ERP automation, and the D2C platform launch in early 2027.

Management Commentary and Tone:

• Tone is highly confident and optimistic, characterizing Q3 as the "strongest in the company's history" and validating the transition from stabilization to acceleration.
• CEO Scott Harvey and CFO Brian Harvey emphasized "operating leverage," demonstrating that incremental sales are flowing to the bottom line with disciplined cost control.
• Management framed the exit of non-performing categories (HT9, Spike, Pop) as strategic discipline rather than failure, focusing resources on higher-return opportunities.
• The narrative focuses on "building a fundamentally stronger business" with a diversified growth strategy that mitigates reliance on single franchises.

Analyst Questions and Answers:

• Future Outlook: Management confirmed no 2027 guidance yet but expects an S-1 update before year-end for a Q1 2027 uplisting.
• Margins: Gross margins are projected to stabilize in the upper 30s, potentially reaching the 40s as high-margin D2C sales mix increases and COGS are leveraged.
• Product Strategy: Zero Sugar products are a core strategic pillar; "Spike Jones" and "Pop Jones" have been discontinued.
• Partnerships: While no specific deals were named, management hinted at new consumer lifestyle partnerships (similar to Crayola/Fallout) to be announced soon.
• Functional Health: Jones Labs will test products targeting metabolic health and GLP-1 support in Q1 2027, based on clinical data and market trends.
• D2C: A new website is under construction to improve conversion and user experience, scheduled for a January 2027 relaunch.

Other Key Points:

• The company successfully navigated a shift in shipment timing, recognizing $2 million in Q3 sales that were previously booked in Q2.
• Implementation of new financial systems, including ERP-based requisitions and standard costing, is underway to enhance visibility and controls as the business scales.
• The team celebrated the 30th anniversary of the brand, leveraging it for limited edition collaborations to strengthen brand loyalty.
• Management explicitly stated they will not "throw money at" underperforming products, reinforcing a disciplined approach to capital allocation.
• The D2C channel's success with high-priced collectibles demonstrates the brand's ability to drive premium pricing and deep consumer engagement.